Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

The report 'Acyl CoA Desaturase - Pipeline Review, H2 2017' outlays comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

'Acyl CoA Desaturase - Pipeline Review, H2 2017'; Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Acyl CoA Desaturase Stearoyl-CoA desaturase 1 is a protein encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid profile of these lipids and produces diverse effects on cellular function.

High SCD1 expression is correlated with metabolic diseases such as obesity and insulin resistance, whereas low levels are protective against these metabolic disturbances. SCD1 is also involved in the regulation of inflammation and stress in distinct cell types, including -cells, adipocytes, macrophages, endothelial cells, and myocytes. Complete loss of SCD1 expression has been implicated in liver dysfunction and several inflammatory diseases such as dermatitis, atherosclerosis, and intestinal colitis.

Key Topics Covered:

1. Introduction
2. Overview
3. Therapeutics Development
4. Products under Development by Stage of Development
5. Products under Development by Therapy Area
6. Products under Development by Indication
7. Products under Development by Companies
8. Therapeutics Assessment
9. Assessment by Mechanism of Action
10. Assessment by Route of Administration
11. Assessment by Molecule Type
12. Companies Involved in Therapeutics Development

• Daiichi Sankyo Co Ltd
• Galmed Pharmaceuticals Ltd
• Johnson & Johnson
• Novartis AG
• Takeda Pharmaceutical Co Ltd
• Thesan Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/research/8ff7pj/acyl_coa